{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:07:42Z","timestamp":1792782462608,"version":"4.5.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Universit\u00e9 d'Angers","id":[{"id":"https:\/\/ror.org\/04yrqp957","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00198-026-07918-6","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T08:34:57Z","timestamp":1772786097000},"page":"1539-1551","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of traditional and new treatments for fibrous dysplasia: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4953-6933","authenticated-orcid":false,"given":"Lucie","family":"Levaillant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Mabilleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ad\u00e8le","family":"Malagi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sixtine","family":"Donat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9gis","family":"Coutant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Rodien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Briet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"issue":"6","key":"7918_CR1","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1210\/clinem\/dgad744","volume":"109","author":"ME Meier","year":"2024","unstructured":"Meier ME et al (2024) Incidence and prevalence of fibrous dysplasia\/McCune-Albright syndrome: a nationwide registry-based study in Denmark. J Clin Endocrinol Metab 109(6):1423\u20131432. https:\/\/doi.org\/10.1210\/clinem\/dgad744","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"7918_CR2","doi-asserted-by":"publisher","first-page":"R83","DOI":"10.1530\/EJE-19-0969","volume":"182","author":"LF de Castro","year":"2020","unstructured":"de Castro LF, Ovejero D, Boyce AM (2020) DIAGNOSIS OF ENDOCRINE DISEASE: Mosaic disorders of FGF23 excess: Fibrous dysplasia\/McCune-Albright syndrome and cutaneous skeletal hypophosphatemia syndrome. Eur J Endocrinol 182(5):R83\u2013R99. https:\/\/doi.org\/10.1530\/EJE-19-0969","journal-title":"Eur J Endocrinol"},{"key":"7918_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0629-x","author":"BCJ Majoor","year":"2017","unstructured":"Majoor BCJ et al (2017) Determinants of impaired quality of life in patients with fibrous dysplasia. Orphanet J Rare Dis. https:\/\/doi.org\/10.1186\/s13023-017-0629-x","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"7918_CR4","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/(sici)1096-9896(199901)187:2<249::aid-path222>3.0.co;2-j","volume":"187","author":"M Riminucci","year":"1999","unstructured":"Riminucci M et al (1999) The histopathology of fibrous dysplasia of bone in patients with activating mutations of the Gs alpha gene: site-specific patterns and recurrent histological hallmarks. J Pathol 187(2):249\u2013258. https:\/\/doi.org\/10.1002\/(sici)1096-9896(199901)187:2%3c249::aid-path222%3e3.0.co;2-j","journal-title":"J Pathol"},{"issue":"1","key":"7918_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227279","volume":"15","author":"D Raimondo","year":"2020","unstructured":"Raimondo D et al (2020) Changes in gene expression in human skeletal stem cells transduced with constitutively active Gs\u03b1 correlates with hallmark histopathological changes seen in fibrous dysplastic bone. PLoS ONE 15(1):e0227279. https:\/\/doi.org\/10.1371\/journal.pone.0227279","journal-title":"PLoS ONE"},{"issue":"7","key":"7918_CR6","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1359\/jbmr.2003.18.7.1235","volume":"18","author":"A Corsi","year":"2003","unstructured":"Corsi A et al (2003) Osteomalacic and hyperparathyroid changes in fibrous dysplasia of bone: core biopsy studies and clinical correlations. J Bone Miner Res 18(7):1235\u20131246. https:\/\/doi.org\/10.1359\/jbmr.2003.18.7.1235","journal-title":"J Bone Miner Res"},{"issue":"9","key":"7918_CR7","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1016\/j.ajhg.2025.07.018","volume":"112","author":"KL Wentworth","year":"2025","unstructured":"Wentworth KL et al (2025) Single-cell analysis of human fibrous dysplasia bone reveals a fibrotic transcriptome and GNAS variants in endothelial, perivascular, and stromal cells. Am J Hum Genet 112(9):2067\u20132087. https:\/\/doi.org\/10.1016\/j.ajhg.2025.07.018","journal-title":"Am J Hum Genet"},{"issue":"1","key":"7918_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1102-9","volume":"14","author":"MK Javaid","year":"2019","unstructured":"Javaid MK et al (2019) Best practice management guidelines for fibrous dysplasia\/McCune-Albright syndrome: a consensus statement from the FD\/MAS international consortium. Orphanet J Rare Dis 14(1):139. https:\/\/doi.org\/10.1186\/s13023-019-1102-9","journal-title":"Orphanet J Rare Dis"},{"key":"7918_CR9","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"issue":"10","key":"7918_CR10","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.11124\/JBISRIR-D-19-00099","volume":"18","author":"Z Munn","year":"2020","unstructured":"Munn Z et al (2020) Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth 18(10):2127\u20132133. https:\/\/doi.org\/10.11124\/JBISRIR-D-19-00099","journal-title":"JBI Evid Synth"},{"key":"7918_CR11","unstructured":"Scottish Intercollegiate Guidelines Network [Internet] (2021) Checklists Edinburgh Health Care Improvement Scotland. [Online]. Available: https:\/\/www.sign.ac.uk\/using-our-guidelines\/methodology\/checklists\/. Accessed 18 Oct 2024"},{"key":"7918_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.envint.2024.108602","volume":"186","author":"JPT Higgins","year":"2024","unstructured":"Higgins JPT et al (2024) A tool to assess risk of bias in non-randomized follow-up studies of exposure effects (ROBINS-E). Environ Int 186:108602. https:\/\/doi.org\/10.1016\/j.envint.2024.108602","journal-title":"Environ Int"},{"key":"7918_CR13","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"7918_CR14","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"7918_CR15","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.envint.2016.01.004","volume":"92\u201393","author":"RL Morgan","year":"2016","unstructured":"Morgan RL et al (2016) GRADE: assessing the quality of evidence in environmental and occupational health. Environ Int 92\u201393:611\u2013616. https:\/\/doi.org\/10.1016\/j.envint.2016.01.004","journal-title":"Environ Int"},{"issue":"8","key":"7918_CR16","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1359\/jbmr.1997.12.8.1314","volume":"12","author":"RS Weinstein","year":"1997","unstructured":"Weinstein RS (1997) Long-term aminobisphosphonate treatment of fibrous dysplasia: spectacular increase in bone density. J Bone Miner Res 12(8):1314\u20131315. https:\/\/doi.org\/10.1359\/jbmr.1997.12.8.1314","journal-title":"J Bone Miner Res"},{"issue":"10","key":"7918_CR17","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1359\/jbmr.1997.12.10.1746","volume":"12","author":"RD Chapurlat","year":"1997","unstructured":"Chapurlat RD, Delmas PD, Liens D, Meunier PJ (1997) Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. J Bone Miner Res 12(10):1746\u20131752. https:\/\/doi.org\/10.1359\/jbmr.1997.12.10.1746","journal-title":"J Bone Miner Res"},{"issue":"2","key":"7918_CR18","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1080\/080352500750028816","volume":"89","author":"R Lala","year":"2000","unstructured":"Lala R, Matarazzo P, Bertelloni S, Buzi F, Rigon F, de Sanctis C (2000) Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome. Acta Paediatr 89(2):188\u2013193. https:\/\/doi.org\/10.1080\/080352500750028816","journal-title":"Acta Paediatr"},{"issue":"3","key":"7918_CR19","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1067\/mpd.2000.107836","volume":"137","author":"M Zacharin","year":"2000","unstructured":"Zacharin M, O\u2019Sullivan M (2000) Intravenous pamidronate treatment of polyostotic fibrous dysplasia associated with the McCune Albright syndrome. J Pediatr 137(3):403\u2013409. https:\/\/doi.org\/10.1067\/mpd.2000.107836","journal-title":"J Pediatr"},{"issue":"2","key":"7918_CR20","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1385\/JCD:4:2:167","volume":"4","author":"MS Parisi","year":"2001","unstructured":"Parisi MS, Oliveri MB, Acotto CG, Mautalen CA (2001) Bone mineral density response to long-term bisphosphonate therapy in fibrous dysplasia. J Clin Densitom 4(2):167\u2013172. https:\/\/doi.org\/10.1385\/JCD:4:2:167","journal-title":"J Clin Densitom"},{"issue":"2","key":"7918_CR21","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00223-001-1098-7","volume":"71","author":"GC Isaia","year":"2002","unstructured":"Isaia GC et al (2002) Bone turnover in children and adolescents with McCune-Albright syndrome treated with pamidronate for bone fibrous dysplasia. Calcif Tissue Int 71(2):121\u2013128. https:\/\/doi.org\/10.1007\/s00223-001-1098-7","journal-title":"Calcif Tissue Int"},{"issue":"4","key":"7918_CR22","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/s8756-3282(03)00221-7","volume":"33","author":"MS Parisi","year":"2003","unstructured":"Parisi MS, Oliveri B, Mautalen CA (2003) Effect of intravenous pamidronate on bone markers and local bone mineral density in fibrous dysplasia. Bone 33(4):582\u2013588. https:\/\/doi.org\/10.1016\/s8756-3282(03)00221-7","journal-title":"Bone"},{"key":"7918_CR23","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030050","author":"H Plotkin","year":"2003","unstructured":"Plotkin H, Rauch F, Zeitlin L, Munns C, Travers R, Glorieux F (2003) Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/jc.2003-030050","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"7918_CR24","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00776-004-0809-0","volume":"9","author":"Y Kitagawa","year":"2004","unstructured":"Kitagawa Y, Tamai K, Ito H (2004) Oral alendronate treatment for polyostotic fibrous dysplasia: a case report. J Orthop Sci 9(5):521\u2013525. https:\/\/doi.org\/10.1007\/s00776-004-0809-0","journal-title":"J Orthop Sci"},{"issue":"1","key":"7918_CR25","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jcms.2003.07.009","volume":"32","author":"M Kos","year":"2004","unstructured":"Kos M, Luczak K, Godzinski J, Klempous J (2004) Treatment of monostotic fibrous dysplasia with pamidronate. J Craniomaxillofac Surg 32(1):10\u201315. https:\/\/doi.org\/10.1016\/j.jcms.2003.07.009","journal-title":"J Craniomaxillofac Surg"},{"issue":"1","key":"7918_CR26","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.bone.2004.03.004","volume":"35","author":"RD Chapurlat","year":"2004","unstructured":"Chapurlat RD, Hugueny P, Delmas PD, Meunier PJ (2004) Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment. Bone 35(1):235\u2013242. https:\/\/doi.org\/10.1016\/j.bone.2004.03.004","journal-title":"Bone"},{"issue":"5","key":"7918_CR27","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/01.ten.0000139003.97250.26","volume":"14","author":"TJ Vokes","year":"2004","unstructured":"Vokes TJ (2004) Fibrous dysplasia: changes during the menstrual cycle and in response to zoledronate. Endocrinologist 14(5):245. https:\/\/doi.org\/10.1097\/01.ten.0000139003.97250.26","journal-title":"Endocrinologist"},{"issue":"1","key":"7918_CR28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1515\/jpem.2006.19.1.75","volume":"19","author":"B Chan","year":"2006","unstructured":"Chan B, Zacharin M (2006) Pamidronate treatment of polyostotic fibrous dysplasia: failure to prevent expansion of dysplastic lesions during childhood. J Pediatr Endocrinol Metab 19(1):75\u201380. https:\/\/doi.org\/10.1515\/jpem.2006.19.1.75","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"Suppl 2","key":"7918_CR29","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1515\/jpem.2006.19.s2.583","volume":"19","author":"R Lala","year":"2006","unstructured":"Lala R et al (2006) Bisphosphonate treatment of bone fibrous dysplasia in McCune-Albright syndrome. J Pediatr Endocrinol Metab 19(Suppl 2):583\u2013593. https:\/\/doi.org\/10.1515\/jpem.2006.19.s2.583","journal-title":"J Pediatr Endocrinol Metab"},{"key":"7918_CR30","first-page":"25","volume":"70","author":"M Jayaraman","year":"2008","unstructured":"Jayaraman M, Hari Kumar K, Verma A, Modi K (2008) Long term alendronate in polyostotic fibrous dysplasia. Horm Res 70:25\u201325","journal-title":"Horm Res"},{"issue":"6","key":"7918_CR31","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s10067-008-0842-z","volume":"27","author":"AA M\u00e4kitie","year":"2008","unstructured":"M\u00e4kitie AA, T\u00f6rnwall J, M\u00e4kitie O (2008) Bisphosphonate treatment in craniofacial fibrous dysplasia--a case report and review of the literature. Clin Rheumatol 27(6):809\u2013812. https:\/\/doi.org\/10.1007\/s10067-008-0842-z","journal-title":"Clin Rheumatol"},{"issue":"2","key":"7918_CR32","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.curtheres.2009.03.003","volume":"70","author":"MS Parisi","year":"2009","unstructured":"Parisi MS, Oliveri B (2009) Long-term pamidronate treatment of polyostotic fibrous dysplasia of bone: a case series in young adults. Curr Ther Res Clin Exp 70(2):161\u2013172. https:\/\/doi.org\/10.1016\/j.curtheres.2009.03.003","journal-title":"Curr Ther Res Clin Exp"},{"key":"7918_CR33","doi-asserted-by":"publisher","first-page":"432060","DOI":"10.1155\/2010\/432060","volume":"2010","author":"ALA Arag\u00e3o","year":"2010","unstructured":"Arag\u00e3o ALA, Silva IN (2010) Oral alendronate treatment for severe polyostotic fibrous dysplasia due to McCune-Albright syndrome in a child: a case report. Int J Pediatr Endocrinol 2010:432060. https:\/\/doi.org\/10.1155\/2010\/432060","journal-title":"Int J Pediatr Endocrinol"},{"key":"7918_CR34","unstructured":"Marcucci G et al (2010) Pamidronate treatment in a patient with fibrous dysplasia of the jaw and FGF-23 mutation, Abstract at the IOF World Congress on Osteoporosis\/10th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, pp 304. https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-010-1247-9.pdf"},{"issue":"7","key":"7918_CR35","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s13312-010-0123-1","volume":"47","author":"IPS Kochar","year":"2010","unstructured":"Kochar IPS, Kulkarni KP (2010) Pamidronate for fibrous dysplasia due to McCune Albright Syndrome. Indian Pediatr 47(7):633\u2013635","journal-title":"Indian Pediatr"},{"key":"7918_CR36","unstructured":"Jayaraman M, Karikumar K, Verma A, Modi KD (2011) Alendronate Therapy in Polyostotic Fibrous Dysplasia Presenting With Pathologic Fracture.\u00a0Am J Orthop 40(3):E48\u2013E50"},{"issue":"6","key":"7918_CR37","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.3892\/ol.2011.369","volume":"2","author":"G-D Li","year":"2011","unstructured":"Li G-D et al (2011) Long-term efficacy of oral alendronate therapy in an elderly patient with polyostotic fibrous dysplasia: a case report. Oncol Lett 2(6):1239\u20131242. https:\/\/doi.org\/10.3892\/ol.2011.369","journal-title":"Oncol Lett"},{"issue":"11","key":"7918_CR38","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1210\/jc.2014-1371","volume":"99","author":"AM Boyce","year":"2014","unstructured":"Boyce AM et al (2014) A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone. J Clin Endocrinol Metab 99(11):4133\u20134140. https:\/\/doi.org\/10.1210\/jc.2014-1371","journal-title":"J Clin Endocrinol Metab"},{"key":"7918_CR39","doi-asserted-by":"publisher","first-page":"670809","DOI":"10.1155\/2015\/670809","volume":"2015","author":"N Ozdemir Kutbay","year":"2015","unstructured":"Ozdemir Kutbay N, Sarer Yurekli B, Kartal Baykan E, Baydur Sahin S, Saygili F (2015) Characteristics and treatment results of 5 patients with fibrous dysplasia and review of the literature. Case Rep Endocrinol 2015:670809. https:\/\/doi.org\/10.1155\/2015\/670809","journal-title":"Case Rep Endocrinol"},{"issue":"2","key":"7918_CR40","doi-asserted-by":"publisher","first-page":"95","DOI":"10.14245\/kjs.2015.12.2.95","volume":"12","author":"J Lee","year":"2015","unstructured":"Lee J, Shin H, Kwon Y-J (2015) Treatment of polyostotic fibrous dysplasia of the thoracic spine with intravenous pamidronate: result from 9 months follow up. Korean J Spine 12(2):95\u201398. https:\/\/doi.org\/10.14245\/kjs.2015.12.2.95","journal-title":"Korean J Spine"},{"issue":"11","key":"7918_CR41","doi-asserted-by":"publisher","first-page":"901","DOI":"10.14740\/jocmr2318w","volume":"7","author":"I Ohno","year":"2015","unstructured":"Ohno I, Higuchi C (2015) Zoledronate therapy for the pathological humeral fracture in polyostotic fibrous dysplasia: a case report. J Clin Med Res 7(11):901\u2013906. https:\/\/doi.org\/10.14740\/jocmr2318w","journal-title":"J Clin Med Res"},{"issue":"10","key":"7918_CR42","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1093\/rheumatology\/kew284","volume":"55","author":"H Florez","year":"2016","unstructured":"Florez H, Peris P, Vidal-Sicart S, Monegal A, Gua\u00f1abens N (2016) Lack of scintigraphic response of fibrous dysplasia to bisphosphonate treatment. Rheumatology (Oxford) 55(10):1735. https:\/\/doi.org\/10.1093\/rheumatology\/kew284","journal-title":"Rheumatology (Oxford)"},{"key":"7918_CR43","unstructured":"Ganesh H (2018) Polyostotic Fibrous Dysplasia of McCune Albright Syndrome responding to intravenous Zoledronate therapy. Posters from 57ESPE congress.\u00a0https:\/\/www.postersessiononline.eu\/pr\/aula_poster.asp?congreso=172191798&grupos=si&swAccesoAdmin=1&poster_directo=si&cod_directo=363698303"},{"issue":"4","key":"7918_CR44","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/jbmr.3649","volume":"34","author":"P Florenzano","year":"2019","unstructured":"Florenzano P et al (2019) Age-related changes and effects of bisphosphonates on bone turnover and disease progression in fibrous dysplasia of bone. J Bone Miner Res 34(4):653\u2013660. https:\/\/doi.org\/10.1002\/jbmr.3649","journal-title":"J Bone Miner Res"},{"issue":"1","key":"7918_CR45","doi-asserted-by":"publisher","first-page":"23","DOI":"10.4158\/EP-2018-0328","volume":"25","author":"Y Wang","year":"2019","unstructured":"Wang Y et al (2019) Efficacy and safety of bisphosphonate therapy in Mccune-Albright syndrome\u2013related polyostotic fibrous dysplasia: a single-center experience. Endocr Pract 25(1):23\u201330. https:\/\/doi.org\/10.4158\/EP-2018-0328","journal-title":"Endocr Pract"},{"key":"7918_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2020.582316","volume":"8","author":"SK Tripathy","year":"2020","unstructured":"Tripathy SK et al (2020) Response to zoledronic acid infusion in children with fibrous dysplasia. Front Pediatr 8:582316. https:\/\/doi.org\/10.3389\/fped.2020.582316","journal-title":"Front Pediatr"},{"issue":"2","key":"7918_CR47","doi-asserted-by":"publisher","first-page":"247","DOI":"10.20945\/2359-3997000000459","volume":"66","author":"LP Valadares","year":"2022","unstructured":"Valadares LP et al (2022) Effects of zoledronic acid therapy in fibrous dysplasia of bone: a single-center experience. Arch Endocrinol Metab 66(2):247\u2013255. https:\/\/doi.org\/10.20945\/2359-3997000000459","journal-title":"Arch Endocrinol Metab"},{"issue":"6","key":"7918_CR48","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1007\/s00405-024-08595-z","volume":"281","author":"I Vilos","year":"2024","unstructured":"Vilos I, Nieminen MT, M\u00e4kitie RE (2024) Fibrous dysplasia of the head and neck in Southern Finland: a retrospective study on clinical characteristics, diagnostics, and treatment. Eur Arch Otorhinolaryngol 281(6):3189\u20133195. https:\/\/doi.org\/10.1007\/s00405-024-08595-z","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"3","key":"7918_CR49","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/s1368-8375(02)00037-4","volume":"39","author":"T Yasuoka","year":"2003","unstructured":"Yasuoka T, Takagi N, Hatakeyama D, Yokoyama K (2003) Fibrous dysplasia in the maxilla: possible mechanism of bone remodeling by calcitonin treatment. Oral Oncol 39(3):301\u2013305. https:\/\/doi.org\/10.1016\/s1368-8375(02)00037-4","journal-title":"Oral Oncol"},{"issue":"7","key":"7918_CR50","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1002\/jbmr.1603","volume":"27","author":"AM Boyce","year":"2012","unstructured":"Boyce AM et al (2012) Denosumab treatment for fibrous dysplasia. J Bone Miner Res 27(7):1462\u20131470. https:\/\/doi.org\/10.1002\/jbmr.1603","journal-title":"J Bone Miner Res"},{"issue":"2","key":"7918_CR51","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s00198-013-2585-1","volume":"25","author":"K Ganda","year":"2014","unstructured":"Ganda K, Seibel MJ (2014) Rapid biochemical response to denosumab in fibrous dysplasia of bone: report of two cases. Osteoporos Int 25(2):777\u2013782. https:\/\/doi.org\/10.1007\/s00198-013-2585-1","journal-title":"Osteoporos Int"},{"issue":"6","key":"7918_CR52","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jbspin.2014.04.013","volume":"81","author":"J Benhamou","year":"2014","unstructured":"Benhamou J, Gensburger D, Chapurlat R (2014) Transient improvement of severe pain from fibrous dysplasia of bone with denosumab treatment. Joint Bone Spine 81(6):549\u2013550. https:\/\/doi.org\/10.1016\/j.jbspin.2014.04.013","journal-title":"Joint Bone Spine"},{"issue":"3","key":"7918_CR53","doi-asserted-by":"publisher","first-page":"253","DOI":"10.11138\/ccmbm\/2016.13.3.253","volume":"13","author":"C Eller-Vainicher","year":"2016","unstructured":"Eller-Vainicher C et al (2016) Prompt clinical and biochemical response to denosumab in a young adult patient with craniofacial fibrous dysplasia. Clin Cases Miner Bone Metab 13(3):253\u2013256. https:\/\/doi.org\/10.11138\/ccmbm\/2016.13.3.253","journal-title":"Clin Cases Miner Bone Metab"},{"issue":"12","key":"7918_CR54","doi-asserted-by":"publisher","first-page":"6069","DOI":"10.1210\/jc.2018-02543","volume":"104","author":"BCJ Majoor","year":"2019","unstructured":"Majoor BCJ, Papapoulos SE, Dijkstra PDS, Fiocco M, Hamdy NAT, Appelman-Dijkstra NM (2019) Denosumab in patients with fibrous dysplasia previously treated with bisphosphonates. J Clin Endocrinol Metab 104(12):6069\u20136078. https:\/\/doi.org\/10.1210\/jc.2018-02543","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"7918_CR55","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jbspin.2020.03.007","volume":"87","author":"KP Gautam","year":"2020","unstructured":"Gautam KP, Rajan R, Cherian KE, Kapoor N, Hephzibah J, Paul TV (2020) A case of recalcitrant fibrous dysplasia treated with denosumab. Joint Bone Spine 87(4):369\u2013370. https:\/\/doi.org\/10.1016\/j.jbspin.2020.03.007","journal-title":"Joint Bone Spine"},{"key":"7918_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2021.101058","volume":"14","author":"ME Meier","year":"2021","unstructured":"Meier ME, van der Bruggen W, van de Sande MAJ, Appelman-Dijkstra NM (2021) Regression of fibrous dysplasia in response to denosumab therapy: a report of two cases. Bone Rep 14:101058. https:\/\/doi.org\/10.1016\/j.bonr.2021.101058","journal-title":"Bone Rep"},{"issue":"49","key":"7918_CR57","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000028138","volume":"100","author":"K Ikuta","year":"2021","unstructured":"Ikuta K, Sakai T, Koike H, Ito K, Imagama S, Nishida Y (2021) Successful treatment with denosumab for pelvic fibrous dysplasia: a case report and review of the literature. Medicine (Baltimore) 100(49):e28138. https:\/\/doi.org\/10.1097\/MD.0000000000028138","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"7918_CR58","doi-asserted-by":"publisher","first-page":"e2980","DOI":"10.1210\/clinem\/dgab212","volume":"106","author":"W van der Bruggen","year":"2021","unstructured":"van der Bruggen W et al (2021) Denosumab reduces lesional fluoride skeletal burden on Na[18F]F PET-CT in patients with fibrous dysplasia\/McCune-Albright syndrome. J Clin Endocrinol Metab 106(8):e2980\u2013e2994. https:\/\/doi.org\/10.1210\/clinem\/dgab212","journal-title":"J Clin Endocrinol Metab"},{"key":"7918_CR59","doi-asserted-by":"crossref","unstructured":"Raborn LN, Burke AB, Ebb D, Collins MT, Kaban LB, Boyce AM (2021) Denosumab for craniofacial fibrous dysplasia: duration of efficacy and post-treatment effects. Osteoporosis International. Osteoporos Int 32:1889\u20131893","DOI":"10.1007\/s00198-021-05895-6"},{"issue":"9","key":"7918_CR60","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1002\/jbmr.4380","volume":"36","author":"ME Meier","year":"2021","unstructured":"Meier ME et al (2021) Safety of therapy with and withdrawal from denosumab in fibrous dysplasia and McCune-Albright syndrome: an observational study. J Bone Miner Res 36(9):1729\u20131738. https:\/\/doi.org\/10.1002\/jbmr.4380","journal-title":"J Bone Miner Res"},{"issue":"8","key":"7918_CR61","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1056\/NEJMc2214862","volume":"388","author":"LF de Castro","year":"2023","unstructured":"de Castro LF et al (2023) Safety and efficacy of denosumab for fibrous dysplasia of bone. N Engl J Med 388(8):766\u2013768. https:\/\/doi.org\/10.1056\/NEJMc2214862","journal-title":"N Engl J Med"},{"key":"7918_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2023.116819","volume":"174","author":"MC Trojani","year":"2023","unstructured":"Trojani MC et al (2023) Denosumab use in bone fibrous dysplasia refractory to bisphosphonate: a retrospective multicentric study. Bone 174:116819. https:\/\/doi.org\/10.1016\/j.bone.2023.116819","journal-title":"Bone"},{"key":"7918_CR63","doi-asserted-by":"publisher","unstructured":"V. Szymczuk et al (2024) \u201cSafety and Efficacy of Moderate-Dose Denosumab in Fibrous Dysplasia: Observational Results from a Phase 2 Clinical Trial\u201d. J Clin Endocrinol Metab dgae867. https:\/\/doi.org\/10.1210\/clinem\/dgae867","DOI":"10.1210\/clinem\/dgae867"},{"key":"7918_CR64","doi-asserted-by":"publisher","DOI":"10.1155\/crie\/4553039","volume":"2025","author":"D Liu","year":"2025","unstructured":"Liu D, Chen J, Chen H, Hu W, Lin J (2025) Rebound hypercalcemia after denosumab cessation in adult fibrous dysplasia: a case report and clinical alert. Case Rep Endocrinol 2025:4553039. https:\/\/doi.org\/10.1155\/crie\/4553039","journal-title":"Case Rep Endocrinol"},{"issue":"1","key":"7918_CR65","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/MPH.0000000000003148","volume":"48","author":"\u00d6 Yildirim \u015ealba\u015f","year":"2026","unstructured":"Yildirim \u015ealba\u015f \u00d6 et al (2026) No regression with imatinib treatment for craniofacial fibrous dysplasia associated with McCune-Albright syndrome. J Pediatr Hematol Oncol 48(1):60\u201361. https:\/\/doi.org\/10.1097\/MPH.0000000000003148","journal-title":"J Pediatr Hematol Oncol"},{"key":"7918_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2022.116343","volume":"157","author":"R Chapurlat","year":"2022","unstructured":"Chapurlat R, Gensburger D, Trolliet C, Rouanet S, Mehsen-Cetre N, Orcel P (2022) Inhibition of IL-6 in the treatment of fibrous dysplasia of bone: the randomized double-blind placebo-controlled TOCIDYS trial. Bone 157:116343. https:\/\/doi.org\/10.1016\/j.bone.2022.116343","journal-title":"Bone"},{"key":"7918_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.116004","author":"A Gladding","year":"2021","unstructured":"Gladding A, Szymczuk V, Auble B, Boyce A (2021) Burosumab treatment for fibrous dysplasia. Bone. https:\/\/doi.org\/10.1016\/j.bone.2021.116004","journal-title":"Bone"},{"key":"7918_CR68","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2106\/JBJS.CC.24.00279","volume":"14","author":"K Sawamura","year":"2024","unstructured":"Sawamura K, Hamajima T, Kitoh H (2024) Improvement of Fibrous Dysplasia After Burosumab Therapy in a Pediatric Patient with McCune-Albright Syndrome: A Case Report. JBJS Case Connect 14:3. https:\/\/doi.org\/10.2106\/JBJS.CC.24.00279","journal-title":"JBJS Case Connect"},{"key":"7918_CR69","doi-asserted-by":"publisher","DOI":"10.1159\/000527129","author":"LJ Apperley","year":"2023","unstructured":"Apperley LJ, Senniappan S (2023) Burosumab therapy in a paediatric patient with McCune-Albright Syndrome: a case report. Horm Res Paediatr. https:\/\/doi.org\/10.1159\/000527129","journal-title":"Horm Res Paediatr"},{"issue":"5","key":"7918_CR70","doi-asserted-by":"publisher","DOI":"10.1093\/jbmrpl\/ziaf042","volume":"9","author":"SD Sakka","year":"2025","unstructured":"Sakka SD et al (2025) Burosumab treatment of a child with McCune-Albright syndrome\/polyostotic fibrous dysplasia: challenges and benefits. JBMR Plus 9(5):ziaf042. https:\/\/doi.org\/10.1093\/jbmrpl\/ziaf042","journal-title":"JBMR Plus"},{"issue":"9","key":"7918_CR71","doi-asserted-by":"publisher","DOI":"10.1093\/jbmrpl\/ziaf125","volume":"9","author":"M Stelmachowska-Bana\u015b","year":"2025","unstructured":"Stelmachowska-Bana\u015b M, Cylke-Falkowska K, Zgliczy\u0144ski W, Bilezikian JP, Misiorowski W (2025) Burosumab treatment for fibroblast growth factor-23-associated hypophosphatemia in an adult patient with severe fibrous dysplasia in McCune-Albright syndrome: case report and review of the literature. JBMR Plus 9(9):ziaf125. https:\/\/doi.org\/10.1093\/jbmrpl\/ziaf125","journal-title":"JBMR Plus"},{"key":"7918_CR72","doi-asserted-by":"publisher","DOI":"10.1101\/2025.09.26.25334161","author":"O de Jong","year":"2025","unstructured":"de Jong O et al (2025) A phase 2 trial of burosumab for treatment of fibroblast growth factor-23 mediated hypophosphatemia in children and adults with fibrous dysplasia. medRxiv. https:\/\/doi.org\/10.1101\/2025.09.26.25334161","journal-title":"medRxiv"},{"issue":"4","key":"7918_CR73","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/jbmr\/zjae023","volume":"39","author":"AS Kim","year":"2024","unstructured":"Kim AS et al (2024) Temporal patterns of osteoclast formation and activity following withdrawal of RANKL inhibition. J Bone Miner Res 39(4):484\u2013497. https:\/\/doi.org\/10.1093\/jbmr\/zjae023","journal-title":"J Bone Miner Res"},{"issue":"3","key":"7918_CR74","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1093\/jbmr\/zjaf008","volume":"40","author":"AS Kim","year":"2025","unstructured":"Kim AS et al (2025) Early and multiple doses of zoledronate mitigates rebound bone loss following withdrawal of receptor activator of nuclear factor kappa-B ligand inhibition. J Bone Miner Res 40(3):413\u2013427. https:\/\/doi.org\/10.1093\/jbmr\/zjaf008","journal-title":"J Bone Miner Res"},{"issue":"8","key":"7918_CR75","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756\u2013765. https:\/\/doi.org\/10.1056\/NEJMoa0809493","journal-title":"N Engl J Med"},{"issue":"2","key":"7918_CR76","doi-asserted-by":"publisher","first-page":"105954","DOI":"10.1016\/j.jbspin.2025.105954","volume":"93","author":"Y Degbo\u00e9","year":"2025","unstructured":"Degbo\u00e9 Y, Couture G (2025) Strategies for denosumab discontinuation in postmenopausal osteoporosis. Joint Bone Spine 93(2):105954. https:\/\/doi.org\/10.1016\/j.jbspin.2025.105954","journal-title":"Joint Bone Spine"},{"issue":"2","key":"7918_CR77","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1210\/endrev\/bnz011","volume":"41","author":"AM Boyce","year":"2020","unstructured":"Boyce AM, Collins MT (2020) Fibrous Dysplasia\/McCune-Albright Syndrome: a rare, mosaic disease of G\u03b1\u200as activation. Endocr Rev 41(2):345\u2013370. https:\/\/doi.org\/10.1210\/endrev\/bnz011","journal-title":"Endocr Rev"},{"issue":"2","key":"7918_CR78","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1359\/JBMR.041111","volume":"20","author":"MT Collins","year":"2005","unstructured":"Collins MT et al (2005) An instrument to measure skeletal burden and predict functional outcome in fibrous dysplasia of bone. J Bone Miner Res 20(2):219\u2013226. https:\/\/doi.org\/10.1359\/JBMR.041111","journal-title":"J Bone Miner Res"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-07918-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-07918-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-07918-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:06:23Z","timestamp":1791950783000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-026-07918-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":78,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7918"],"URL":"https:\/\/doi.org\/10.1007\/s00198-026-07918-6","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"assertion":[{"value":"18 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Lucie Levaillant, Guillaume Mabilleau, Ad\u00e8le Malagi\u00e9, Sixtine Donat, R\u00e9gis Coutant, Patrice Rodien et Claire Briet declare that they have no conflict of interest regarding the publication of this paper.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}